In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Marsh & McLennan’s current price implies a 41.8% undervaluation relative to high-confidence fair value estimates, supported by strong DCF and EV/EBITDA valuations. Despite fair financial health and low growth scores, profitability is robust, yet Monte Carlo analysis shows high volatility with downside risk at 22.2%. The wide valuation range signals significant uncertainty but also notable upside potential.